Expert panelists review data presented at ASCO 2023 and surrounding meetings to elucidate the current treatment landscape of renal cell carcinoma.
EP. 3: Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
EP. 9: Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
EP. 15: Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
October 27th 2023Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.
EP. 16: Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
October 27th 2023Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.
EP. 17: Future Perspectives in the Treatment of Advanced RCC
November 3rd 2023Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.